Stock Analysis
Biogen Inc. Common StockBIIB
P/E 41.19×· 5Y range 11.24–41.67×· top 0% of history
Sector: Healthcare · Industry: Biotechnology
AnalystsStrong Buy43 analystsP/E 41.2× sits at the 100th percentile of its 5.089664613278576-year history.
No reported debt · FY 2025.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Financial Health85
- Quality64
Risks
- Valuation52
- Growth25
Mixed fundamentals at a demanding price.
Bull Case
- ✓Altman Z 3.6 — safe-zone balance sheet
What's happening with BIIB
Profile
Strong moat and financial health; growth and profitability lag behind.
How is each axis scored?
- Valuation52/100 · Moderate
- P/E vs own history (100th pct)0/25
- FCF yield (7.8%)20/25
- P/S (3.4x)20/25
- EV/EBIT (19.1x)12/25
- Growth25/100 · Weak
- Revenue CAGR (-2.6%)0/25
- Net income CAGR (-4.5%)0/25
- EPS CAGR 5Y (-4.1%)0/25
- Fwd implied growth (179.4%)25/25
- Profitability43/100 · Weak
- ROIC (7.9%)5/25
- ROE (4.6%)5/25
- Net margin (8.3%)13/25
- Operating margin (17.5%)20/25
- Financial Health85/100 · Strong
- Altman Z (3.55)25/25
- Current ratio (2.68)25/25
- Interest coverage (4.2x)10/25
- Net cash / debt (Net cash)25/25
- Quality64/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.17)12/25
- FCF conversion (323%)25/25
- Margin stability (σ 11.8%)12/25
- Moat95/100 · Strong
- ROIC >12% years (8/10 yrs)20/25
- Median gross margin (83.6%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 11.8%)25/25
Risk Flags
- ⚠Revenue shrinking 2.6%/yr
- ⚠P/E 41.2× at top 0% of 5-year history
About Biogen Inc. Common Stock
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Show more
Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Headquarters: CAMBRIDGE, MA · Employees: 7,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
52CP/E (TTM)41.2xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 11.2x–41.7x · highest in history
P/FCF13.9xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield7.8%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.7%–14.7% · 53rd pct
P/S (TTM)3.43xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.7x–4.6x · 69th pct
EV/EBIT19.1xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 3.9x–29.8x · 79th pct
EV/Sales4.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E14.7xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.88xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio7.83D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
43D+ROIC7.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE4.6%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA2.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin8.3%C
Grade C: AverageNet Income / Revenue
Operating Margin17.5%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin74.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin26.9%A
Grade A: HighFCF / Revenue
True FCF Margin23.9%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR-2.6%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-4.5%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-4.1%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth179.4%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-2.3%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income35.5%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue3.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
85AAltman Z-Score3.55A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.68xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.26xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.2xC
Grade C: OkEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / DebtNo DebtA
Grade A: CleanCash covers how much of total debt. >1 = could repay all debt from cash
Quality
64BPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.17C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion323.1%A
Grade A: StrongFCF / Net Income
Margin Stability11.8%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue1.8%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.33xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Godbout Sean Filed | Godbout Sean | Option exercise | -27 | |
Godbout Sean Filed | Godbout Sean | Tax withholding | -8 | |
Godbout Sean Filed | Godbout Sean | Option exercise | +27 | |
Godbout Sean Filed | Godbout Sean | Grant / award | +985 | |
Parini Michael Filed | Parini Michael | Grant / award | +7.4K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Minor Lloyd Filed | Minor Lloyd | SellOpen market sale | -593 | |
Minor Lloyd Filed | Minor Lloyd | SellOpen market sale | -593 | |
Minor Lloyd Filed | Minor Lloyd | Grant / award | +1.5K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
95A+ROIC >12% Years8/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)83.6%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor11.8%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$5.65
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$8.70
Cash & short-term investments per share (Finnhub)
Book Value / Share$127.61
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$0
Total debt obligations (short + long term)
Cash & Equiv.$807.20M
Cash and short-term investments
Net Debt$-807.20MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$18.26B
Shareholders' equity (book value)
Asset / Liability2.63xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$34.37B
Current Market Capitalization
Beta0.10B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Biogen Inc. Common Stock (BIIB)
BIIB is down 1.15% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Biogen Inc. Common Stock. Altman Z-Score of 3.55 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk.
- Revenue has been contracting (CAGR ≈ -3%), which weighs on the growth outlook.
- Biogen Inc. Common Stock converts about 27% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
See how BIIB ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BIIB moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 12 | Pre-market | 233.05 | +3.25% | 2.11 |
| Oct 9 | Regular | 225.71 | +3.33% | 2.68 |
| Oct 9 | After-hours | 225.71 | +3.33% | 2.68 |
Frequently Asked Questions about BIIB
What is the current Biogen Inc. Common Stock (BIIB) stock price?
BIIB is trading at $232.65 at the last market close, down 1.15% on the session. PreMarketPrice tracks BIIB pre-market, intraday and after-hours prices.
Is BIIB stock a buy right now?
PreMarketPrice's quantitative model rates Biogen Inc. Common Stock's financial health at 85/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BIIB stock overvalued?
Biogen Inc. Common Stock trades at a trailing P/E of 41.2 and our valuation score rates it 52/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Biogen Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for BIIB. The Earnings section lists recent reports and updates as dates are announced.
What sector does Biogen Inc. Common Stock operate in?
Biogen Inc. Common Stock operates in the Healthcare sector, within the Biotechnology industry. The Related Stocks section lists sector peers for comparison.
What does Biogen Inc. Common Stock do?
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases.
About Biogen Inc. Common Stock (BIIB) Stock
Biogen Inc. Common Stock (BIIB) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry. As of the latest update, Biogen Inc. Common Stock is trading at $232.65, down 1.15% on the day with a market capitalization of $34.4 billion. The financial health score for BIIB is 85/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BIIB stock.
BIIB Stock Analysis & Key Metrics
On PreMarketPrice, you can track Biogen Inc. Common Stock (BIIB) across multiple dimensions:
- Pre-market price & movement: Real-time BIIB stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BIIB with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Biogen Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 85/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BIIB.
- Sector peers: Compare BIIB against 6 other healthcare stocks on key financial metrics.
Is BIIB a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Biogen Inc. Common Stock (BIIB) as an investment. The financial health score of 85/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Biogen Inc. Common Stock (BIIB) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.